The silent epidemic of gout is reshaping global health patterns, with 57 million people now living with this painful joint condition that disproportionately strikes men and older adults. This metabolic disorder, once considered a disease of affluence, has evolved into a widespread health challenge that transcends economic boundaries while paradoxically intensifying in wealthier regions.
Analysis of three decades of global health data reveals that gout prevalence climbed 21.9% between 1990 and 2021, generating 1.75 million disability-adjusted life years annually. The condition now affects 9.4 million new patients yearly, with men experiencing burden rates 2.8 times higher than women. Socioeconomically developed regions show the steepest increases, suggesting lifestyle and dietary factors amplify genetic predisposition to elevated uric acid levels.
This epidemiological shift reflects broader changes in global nutrition patterns, urbanization, and longevity. The male predominance likely stems from hormonal differences in uric acid metabolism, with estrogen providing protective effects that diminish after menopause. The age-related progression indicates cumulative metabolic dysfunction rather than simple wear-and-tear, positioning gout as both a marker and driver of systemic inflammation. While previous research established gout's link to cardiovascular disease and metabolic syndrome, this comprehensive analysis demonstrates how the condition has evolved from a historical curiosity into a major contributor to global disease burden. The finding that wealthier populations face higher risks challenges assumptions about prosperity and health, suggesting that dietary abundance and sedentary lifestyles may offset medical advances in prevention and treatment.